Cabaletta Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cabaletta Bio, Inc. on June 2, 2022, regarding events occurring on June 1, 2022. The filing details the results of the Company's Annual Meeting of Stockholders held on that date. As of the record date of April 4, 2022, there were 25,064,629 outstanding shares of voting common stock.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes
The primary material event reported is the outcome of the stockholder vote on two proposals:
- Proposal 1 (Director Election): Stockholders approved the election of Steven Nichtberger, M.D., and Mark Simon, MBA, as Class III directors for a three-year term expiring in 2025.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is limited to the tabulation of votes cast at the Annual Meeting.
Key Facts for Investor Verification
- Director Election Results: Steven Nichtberger, M.D. received 11,549,000.97 votes "For" and 3,214,793.33 votes "Withheld". Mark Simon, MBA received 9,338,734.97 votes "For" and 5,402,059.33 votes "Withheld".
- Auditor Ratification Results: The appointment of Ernst & Young LLP received 20,342,893.97 votes "For", 11,645.33 votes "Against", and 5,044 votes "Abstain".
- Broker Non-Votes: There were 5,595,789 broker non-votes recorded for the director elections and 0 broker non-votes for the auditor ratification.
- Share Count: The total outstanding voting common stock as of the record date was 25,064,629 shares.